Literature DB >> 20924730

Establishment of an HS23 stromal cell-dependent myeloma cell line: fibronectin and IL-6 are critical.

Akira Sakai1, Miyo Oda, Mitsuhiro Itagaki, Noriaki Yoshida, Koji Arihiro, Akiro Kimura.   

Abstract

A multiple myeloma (MM) cell line, MSG1, which depends on HS23 stromal cells for its survival, was established from the pleural effusion of a patient with MM who expressed the M-protein of IgA-λ in his serum. During the first 2 months of culture, the myeloma cells survived on adhesive cells from the pleural effusion and, subsequently, they continued to proliferate on HS23 stromal cells. The phenotype of the established MSG1 cell line was: CD138(+), CD38(++), CD19⁻, CD56⁻, VLA-4(+), VEGFR1(+) and VEGFR2(+). Immunohistochemical staining also demonstrated expression of the IgA and λ chain in MSG1 cytoplasm. Karyotype analysis indicated complex chromosomal abnormalities; hypertriploidy, including the deletion of chromosomes 13 and 17, and c-myc translocation. MSG1 cells continued to proliferate, not only when co-cultured with HS23 cells, but also when cultured only on fibronectin-coated plates with the supernatant of HS23 cells or with control medium containing IL-6. Tocilizumab, an anti-IL-6 receptor antibody, inhibited MSG1 survival under these conditions. Therefore, MSG1 may be a unique myeloma cell line that is useful for the study of cell adhesion-mediated drug resistance induced by adhesion molecules and IL-6 stimulation of myeloma cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924730     DOI: 10.1007/s12185-010-0698-2

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Analysis of expressed immunoglobulin heavy chain genes in familial B-CLL.

Authors:  A Sakai; G E Marti; N Caporaso; S Pittaluga; J W Touchman; F Fend; M Raffeld
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

2.  Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.

Authors:  J S Damiano; A E Cress; L A Hazlehurst; A A Shtil; W S Dalton
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

3.  Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.

Authors:  K Podar; Y T Tai; F E Davies; S Lentzsch; M Sattler; T Hideshima; B K Lin; D Gupta; Y Shima; D Chauhan; C Mitsiades; N Raje; P Richardson; K C Anderson
Journal:  Blood       Date:  2001-07-15       Impact factor: 22.113

4.  Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.

Authors:  F Di Raimondo; M P Azzaro; G Palumbo; S Bagnato; G Giustolisi; P Floridia; G Sortino; R Giustolisi
Journal:  Haematologica       Date:  2000-08       Impact factor: 9.941

5.  Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.

Authors:  B Dankbar; T Padró; R Leo; B Feldmann; M Kropff; R M Mesters; H Serve; W E Berdel; J Kienast
Journal:  Blood       Date:  2000-04-15       Impact factor: 22.113

6.  Bortezomib overcomes cell-adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma.

Authors:  K Noborio-Hatano; J Kikuchi; M Takatoku; R Shimizu; T Wada; M Ueda; M Nobuyoshi; I Oh; K Sato; T Suzuki; K Ozaki; M Mori; T Nagai; K Muroi; Y Kano; Y Furukawa; K Ozawa
Journal:  Oncogene       Date:  2008-10-13       Impact factor: 9.867

7.  Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma.

Authors:  D Shibata; L M Weiss; B N Nathwani; R K Brynes; A M Levine
Journal:  Blood       Date:  1991-04-01       Impact factor: 22.113

8.  Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.

Authors:  V Ramakrishnan; M Timm; J L Haug; T K Kimlinger; L E Wellik; T E Witzig; S V Rajkumar; A A Adjei; S Kumar
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

9.  Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.

Authors:  Masahiro Abe; Kenji Hiura; Javier Wilde; Atsushi Shioyasono; Keiji Moriyama; Toshihiro Hashimoto; Shinsuke Kido; Takashi Oshima; Hironobu Shibata; Shuji Ozaki; Daisuke Inoue; Toshio Matsumoto
Journal:  Blood       Date:  2004-06-08       Impact factor: 22.113

10.  Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen.

Authors:  P Monini; L de Lellis; M Fabris; F Rigolin; E Cassai
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245

View more
  3 in total

1.  A 3D-Bioprinted Multiple Myeloma Model.

Authors:  Di Wu; Zongyi Wang; Jun Li; Yan Song; Manuel Everardo Mondragon Perez; Zixuan Wang; Xia Cao; Changliang Cao; Sushila Maharjan; Kenneth C Anderson; Dharminder Chauhan; Yu Shrike Zhang
Journal:  Adv Healthc Mater       Date:  2021-09-23       Impact factor: 11.092

2.  Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone.

Authors:  Yu Zheng; Dennis Basel; Shu-Oi Chow; Colette Fong-Yee; Sarah Kim; Frank Buttgereit; Colin R Dunstan; Hong Zhou; Markus J Seibel
Journal:  Clin Exp Metastasis       Date:  2014-09-16       Impact factor: 5.150

3.  The Cross-Talk between Myeloid and Mesenchymal Stem Cells of Human Bone Marrow Represents a Biomarker of Aging That Regulates Immune Response and Bone Reabsorption.

Authors:  Maria Elisa Perico; Tommaso Maluta; Giamaica Conti; Antonio Vella; Lisa Provezza; Tiziana Cestari; Giulia De Cao; Lydia Segalla; Cristina Tecchio; Fabio Benedetti; Francesco Santini; Vincenzo Bronte; Bruno Magnan; Andrea Sbarbati; Dunia Ramarli
Journal:  Cells       Date:  2021-12-21       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.